| General Information | |
|---|---|
| ZINC ID | ZINC000066111657 |
| Molecular Weight (Da) | 417 |
| SMILES | Clc1cccc2c(-c3nsc(CN4CCCC4)n3)cn(CC3CCOCC3)c12 |
| Molecular Formula | C21Cl1N4O1S1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 115.562 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 28 |
| LogP | 3.771 |
| Activity (Ki) in nM | 19.9526 |
| Polar Surface Area (PSA) | 71.42 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.725 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 14 |
| Fraction csp3 | 0.52 |
| Ilogp | 4.24 |
| Xlogp3 | 4.01 |
| Wlogp | 4.3 |
| Mlogp | 2.44 |
| Silicos-it log p | 5.22 |
| Consensus log p | 4.04 |
| Esol log s | -4.99 |
| Esol solubility (mg/ml) | 0.00425 |
| Esol solubility (mol/l) | 0.0000102 |
| Esol class | Moderately |
| Ali log s | -5.21 |
| Ali solubility (mg/ml) | 0.00256 |
| Ali solubility (mol/l) | 0.00000613 |
| Ali class | Moderately |
| Silicos-it logsw | -6.17 |
| Silicos-it solubility (mg/ml) | 0.000279 |
| Silicos-it solubility (mol/l) | 0.00000066 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.67 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.406 |
| Logd | 3.741 |
| Logp | 4.291 |
| F (20%) | 0.038 |
| F (30%) | 0.082 |
| Mdck | - |
| Ppb | 94.71% |
| Vdss | 2.796 |
| Fu | 5.26% |
| Cyp1a2-inh | 0.736 |
| Cyp1a2-sub | 0.599 |
| Cyp2c19-inh | 0.822 |
| Cyp2c19-sub | 0.062 |
| Cl | 8.419 |
| T12 | 0.022 |
| H-ht | 0.979 |
| Dili | 0.626 |
| Roa | 0.424 |
| Fdamdd | 0.842 |
| Skinsen | 0.099 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.795 |
| Bcf | 1.667 |
| Igc50 | 3.407 |
| Lc50 | 3.944 |
| Lc50dm | 4.344 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.862 |
| Nr-aromatase | 0.916 |
| Nr-er | 0.193 |
| Nr-er-lbd | 0.022 |
| Nr-ppar-gamma | 0.012 |
| Sr-are | 0.74 |
| Sr-atad5 | 0.032 |
| Sr-hse | 0.906 |
| Sr-mmp | 0.453 |
| Sr-p53 | 0.407 |
| Vol | 399.668 |
| Dense | 1.041 |
| Flex | 0.192 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.597 |
| Synth | 2.883 |
| Fsp3 | 0.524 |
| Mce-18 | 61.5 |
| Natural product-likeness | -1.502 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |